These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 7455997

  • 21. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.
    Bhargava AS, Heinick J, Günzel P.
    Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289
    [Abstract] [Full Text] [Related]

  • 22. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U.
    Thromb Haemost; 1982 Jun 28; 47(3):244-8. PubMed ID: 7112499
    [Abstract] [Full Text] [Related]

  • 23. Effect of a pentosan polysulphate upon thrombin and factor Xa inactivation by antithrombin III.
    Scully MF, Kakkar VV.
    Biochem J; 1984 Sep 15; 222(3):571-8. PubMed ID: 6207810
    [Abstract] [Full Text] [Related]

  • 24. The relative molecular mass dependence of the anti-factor Xa properties of heparin.
    Ellis V, Scully MF, Kakkar VV.
    Biochem J; 1986 Sep 01; 238(2):329-33. PubMed ID: 3800942
    [Abstract] [Full Text] [Related]

  • 25. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR, Mourão PA.
    Thromb Haemost; 2008 Mar 01; 99(3):531-8. PubMed ID: 18327401
    [Abstract] [Full Text] [Related]

  • 26. Effects of PGI2 on the inactivation of thrombin, factor Xa, and plasmin by antithrombin-III and heparin.
    Blaskó G.
    Prostaglandins; 1979 Jul 01; 18(1):3-9. PubMed ID: 160589
    [Abstract] [Full Text] [Related]

  • 27. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A, Krachmalnicoff A, Mannucci PM.
    Thromb Haemost; 1986 Dec 15; 56(3):349-52. PubMed ID: 3563966
    [Abstract] [Full Text] [Related]

  • 28. Inherited AT-III deficiency: fast and slow inactivation of thrombin and factor Xa.
    Mortensen JZ.
    Thromb Res; 1984 Mar 01; 33(5):511-5. PubMed ID: 6719397
    [Abstract] [Full Text] [Related]

  • 29. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
    Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, Ofosu FA, Fernandez-Rachubinski F, Andrew M, Hirsh J.
    Thromb Haemost; 1993 Mar 01; 69(3):231-5. PubMed ID: 8470046
    [Abstract] [Full Text] [Related]

  • 30. Purification and further characterization of antithrombin III Milano: lack of reactivity with thrombin.
    Wolf M, Boyer-Neumann C, Meyer D, Tripodi A, Mannucci PM, Larrieu MJ.
    Thromb Haemost; 1987 Oct 28; 58(3):888-92. PubMed ID: 3433251
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L, Dewar L, Song Y, Kulczycky M, Blajchman MA, Fenton JW, Andrew M, Delorme M, Ginsberg J, Preissner KT.
    Thromb Haemost; 1995 Mar 28; 73(3):405-12. PubMed ID: 7545318
    [Abstract] [Full Text] [Related]

  • 32. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G, Blombäck M, Olsson P, Riesenfeld J.
    Thromb Haemost; 1993 Aug 02; 70(2):289-93. PubMed ID: 8236137
    [Abstract] [Full Text] [Related]

  • 33. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.
    Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U.
    Biochem J; 1984 Mar 15; 218(3):725-32. PubMed ID: 6721831
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV, Béguin S, Caplain H, Hemker HC.
    Thromb Haemost; 1994 Mar 15; 71(3):305-13. PubMed ID: 8029794
    [Abstract] [Full Text] [Related]

  • 35. Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia.
    Sas G, Blaskó G, Bánhegyi D, Jákó J, Pálos LA.
    Thromb Diath Haemorrh; 1974 Sep 30; 32(1):105-15. PubMed ID: 4454033
    [Abstract] [Full Text] [Related]

  • 36. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin.
    Huntington JA, Gettins PG.
    Biochemistry; 1998 Mar 10; 37(10):3272-7. PubMed ID: 9521646
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III.
    Baruch D, Lindhout T, Wagenvoord R, Hemker HC.
    Haemostasis; 1986 Mar 10; 16(2):71-81. PubMed ID: 3086193
    [Abstract] [Full Text] [Related]

  • 38. Inactivation of alpha- and beta- thrombin by antithrombin-III and heparin.
    Machovich R, Blaskó G, Borsodi A.
    Thromb Haemost; 1976 Dec 31; 36(3):503-8. PubMed ID: 65798
    [Abstract] [Full Text] [Related]

  • 39. Interaction of thrombin and factor Xa with bovine vascular endothelial cells, smooth muscle cells and rat hepatoma cells.
    Dryjski M, Kuo BS, Bjornsson TD.
    Thromb Haemost; 1988 Oct 31; 60(2):148-52. PubMed ID: 3217915
    [Abstract] [Full Text] [Related]

  • 40. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women].
    Akai Y, Shiga S, Tohyama K, Shimatsu A, Ichiyama S.
    Rinsho Byori; 2000 Sep 31; 48(9):867-71. PubMed ID: 11051806
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.